Abstract
CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ciatto S., Rosselli Del Turco M., Pacini P., Mustacchi G., Simonis M., Sismondi P., Giardina G., Belsanti V., Aristei C., Molino A. M. Early detection of breast cancer recurrences through periodic follow-up--is it useless? Tumori. 1985 Aug 31;71(4):325–329. doi: 10.1177/030089168507100402. [DOI] [PubMed] [Google Scholar]
- Colomer R., Ruibal A., Genollá J., Rubio D., Del Campo J. M., Bodi R., Salvador L. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989 Mar;13(2):123–133. doi: 10.1007/BF01806524. [DOI] [PubMed] [Google Scholar]
- Delarue J. C., Mouriesse H., Dubois F., Friedman S., May-Levin F. Markers in breast cancer: does CEA add to the detection by CA 15.3? Breast Cancer Res Treat. 1988 Jul;11(3):273–276. doi: 10.1007/BF01807287. [DOI] [PubMed] [Google Scholar]
- Gion M., Mione R., Dittadi R., Fasan S., Pallini A., Bruscagnin G. Evaluation of CA15/3 serum levels in breast cancer patients. J Nucl Med Allied Sci. 1986 Jan-Mar;30(1):29–36. [PubMed] [Google Scholar]
- Kindler M., Steinhoff G. Follow-up of breast cancer patients. Oncology. 1989;46(6):360–365. doi: 10.1159/000226751. [DOI] [PubMed] [Google Scholar]
- Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984 Fall;3(3):223–232. doi: 10.1089/hyb.1984.3.223. [DOI] [PubMed] [Google Scholar]
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
- Pons-Anicet D. M., Krebs B. P., Mira R., Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer. 1987 May;55(5):567–569. doi: 10.1038/bjc.1987.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmidt-Rhode P., Schulz K. D., Sturm G., Raab-Frick A., Prinz H. CA 15.3 as a tumour marker in breast cancer. Int J Biol Markers. 1987 Sep-Dec;2(3):135–142. doi: 10.1177/172460088700200301. [DOI] [PubMed] [Google Scholar]
- Urban J. A. Breast cancer 1985. What have we learned? Cancer. 1986 Feb 1;57(3):636–643. doi: 10.1002/1097-0142(19860201)57:3<636::aid-cncr2820570340>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]